How to Get Dayvigo (Lemborexant) in Nevada

What Is Lemborexant and Why Might You Need It

Lemborexant is a dual orexin receptor antagonist (DORA) that blocks OX1R and OX2R signaling to quiet the brain's wake-drive and allow sleep to occur naturally. The FDA approved it under the brand name Dayvigo on December 20, 2019, for adults with insomnia characterized by difficulty with sleep onset, sleep maintenance, or both. Unlike benzodiazepines or Z-drugs, it does not globally suppress the central nervous system; it specifically targets the orexin pathway that keeps you awake [1].

The prescribing information approved by the FDA lists 5 mg as the starting dose, with titration to 10 mg if 5 mg is tolerated but not sufficiently effective [2]. Neither dose should be taken unless the patient has at least seven hours before planned awakening. The drug is metabolized primarily by CYP3A, so concurrent use of strong CYP3A inhibitors (such as ketoconazole or clarithromycin) is contraindicated, and dose reduction is required with moderate CYP3A inhibitors [2].

Chronic insomnia disorder affects roughly 10 to 15 percent of U.S. adults, according to data from the Centers for Disease Control and Prevention [3]. Nevada's population of approximately 3.2 million means tens of thousands of residents may qualify for evaluation. In the SUNRISE-1 trial (N=1,006), lemborexant 10 mg reduced subjective sleep onset latency by 22.8 minutes versus placebo at month 1 (P<0.0001) and maintained that benefit through month 6 [4].

The Clinical Evidence Supporting Dayvigo

SUNRISE-1, published in JAMA Network Open in 2019, was a Phase 3, randomized, double-blind, placebo- and active-controlled study comparing lemborexant 5 mg and 10 mg against zolpidem tartrate extended-release 6.25 mg and placebo over six months in 1,006 adults aged 55 and older [4]. Both lemborexant doses outperformed placebo on the co-primary endpoints of subjective sleep onset latency and sleep efficiency at the end of months 1 and 6 (P<0.001 for each comparison) [4].

SUNRISE-2, the companion 12-month trial (N=949), demonstrated durable efficacy: patients on lemborexant 10 mg reported a mean 28.1-minute improvement in subjective total sleep time at month 12 versus 14.7 minutes for placebo [5]. Discontinuation rates due to adverse events were 4.6 percent for lemborexant 10 mg versus 3.4 percent for placebo, which is a clinically small difference [5].

A 2020 network meta-analysis published in The Lancet compared 30 insomnia medications and found that lemborexant ranked highest for sleep maintenance and second highest for sleep onset among agents with an acceptable safety profile [6]. The American Academy of Sleep Medicine's clinical practice guidelines, updated in 2023, include orexin receptor antagonists as a recommended pharmacological option for chronic insomnia disorder in adults [7].

Somnolence and headache are the two most common adverse events reported across the SUNRISE program, occurring in roughly 10 percent and 8 percent of lemborexant-treated patients respectively at the 10 mg dose [2]. Next-morning impairment, as measured by the Divided Attention Driving Test, was statistically lower with lemborexant 10 mg than with zolpidem ER 6.25 mg at 9 hours post-dose in SUNRISE-1 [4]. Prescribers in Nevada should advise patients not to drive the next morning if they feel impaired.

How Nevada Law Governs Dayvigo Prescriptions

Lemborexant is a Schedule IV controlled substance under both federal DEA scheduling and Nevada Revised Statutes Chapter 453 [8]. In Nevada, Schedule IV prescriptions may be transmitted electronically, by fax, or in writing. Phone-in prescriptions for Schedule IV are permitted for an emergency supply of up to a 72-hour quantity, after which a written or electronic order must follow [9].

Nevada's Prescription Monitoring Program (PMP), operated under the Nevada State Board of Pharmacy, requires dispensers to report Schedule IV controlled substances within one business day of dispensing [9]. Prescribers must query the PMP before issuing an initial lemborexant prescription and at each refill visit. Failure to check the PMP is a disciplinary violation.

Refill rules: Schedule IV prescriptions in Nevada may be refilled up to five times within six months of the original prescription date [9]. After that, a new prescription from a licensed prescriber is required. Many telehealth platforms include refill visits as part of their ongoing care model, so patients do not need to restart the intake process from scratch.

Driving impairment is an active regulatory concern in Nevada. The Nevada Department of Public Safety notes that any driver impaired by a prescribed controlled substance can be charged under NRS 484C.110 regardless of prescription status [10]. Patients should be counseled explicitly on next-morning impairment risk.

Who Can Prescribe Dayvigo in Nevada

Any licensed prescriber with DEA Schedule IV authority can prescribe lemborexant in Nevada. That includes MDs (allopathic physicians), DOs (osteopathic physicians), licensed NPs (nurse practitioners), and PAs (physician assistants) who hold a valid DEA registration [9]. Nevada is a full practice-authority state for NPs, meaning they do not need physician supervision to prescribe Schedule IV controlled substances after completing the required 2,000-hour collaborative practice period [11]. PAs in Nevada operate under a practice agreement but can independently prescribe Schedule IV drugs when the agreement covers that category [11].

In telehealth settings, the Ryan Haight Act requires that a DEA-registered provider have conducted at least one in-person or qualifying telehealth evaluation before prescribing a controlled substance [12]. The DEA's 2023 telemedicine rules, currently operating under extended COVID-era flexibilities, allow prescribing of Schedule IV non-narcotic medications (which includes lemborexant) via audiovisual telehealth without a prior in-person visit, provided the provider is licensed in the patient's state (Nevada) and uses a HIPAA-compliant platform [12].

Getting a Dayvigo Prescription Through Nevada Telehealth

Telehealth prescribing of lemborexant in Nevada is permitted for qualified providers following the applicable DEA and state rules. The visit typically takes 20 to 40 minutes and covers sleep history, the Insomnia Severity Index (ISI) questionnaire, a medication review for CYP3A interactions, and a check of the Nevada PMP. Patients should have the following ready before the visit:

1. A list of all current medications (prescription, OTC, and supplements).
2. Prior sleep study results, if any exist.
3. Insurance card or preferred pharmacy information.
4. A completed sleep diary covering at least one week, if possible.

Providers may screen for obstructive sleep apnea before prescribing. The STOP-BANG questionnaire (Score <3 = low risk) is a validated five-minute tool that can be completed digitally before the visit [13]. Untreated moderate-to-severe sleep apnea is a relative contraindication for lemborexant, since the drug may reduce arousal responses to apneic events [2].

After the visit, the provider sends an electronic prescription to the Nevada-licensed pharmacy of your choice. Most major retail chains in Nevada (CVS, Walgreens, Smith's/Kroger, Walmart) carry lemborexant in both 5 mg and 10 mg strengths, though availability can vary by location. Calling ahead to confirm stock prevents a wasted trip.

Labs and Workup Before Starting Lemborexant

No mandatory laboratory panel is required before prescribing lemborexant, unlike many other controlled sleep agents. The Dayvigo prescribing information does not list any required baseline labs [2]. A practical pre-prescribing assessment for Nevada telehealth providers typically includes the following:

• Insomnia Severity Index score (validated 7-item questionnaire; a score <15 suggests moderate insomnia; <22 suggests severe insomnia) [14].
• Epworth Sleepiness Scale to quantify daytime impairment [15].
• Basic medication reconciliation to flag CYP3A inhibitors or inducers.
• Liver function assessment by history in patients with known hepatic disease, because moderate hepatic impairment requires a 5 mg maximum dose per FDA label [2].

Routine CBC, metabolic panel, or thyroid function tests are not required by the FDA label. Some sleep-medicine providers order a TSH to rule out hypothyroidism as a secondary cause of insomnia, and a fasting glucose or HbA1c in patients with obesity or metabolic syndrome, since sleep deprivation worsens glycemic control [16]. These are clinically reasonable additions, not regulatory requirements.

For patients with suspected sleep apnea, a home sleep apnea test (HSAT) ordered by the telehealth provider before dispensing is a reasonable precaution. Results typically return within one to two weeks from most Nevada-based sleep diagnostic labs.

Dayvigo Pricing, Insurance, and Nevada Medicaid

Nevada Medicaid (Nevada Check Up and Nevada Medicaid fee-for-service) does not currently cover lemborexant [17]. Patients on Medicaid who need a DORA may ask their provider about suvorexant (Belsomra), which has a different formulary status depending on the specific Medicaid managed care organization.

For commercial insurance, most major payers (Anthem Blue Cross of Nevada, Aetna, UnitedHealthcare Nevada) place Dayvigo on Tier 3 or Tier 4 with prior authorization required [18]. A 30-day supply at 10 mg carries a typical list price of approximately $370 to $420 without insurance, based on GoodRx pricing data as of early 2025. With manufacturer savings programs (Eisai's Dayvigo Savings Card), eligible commercially insured patients may pay as little as $30 for a 30-day supply [19].

Prior Authorization Documentation

Nevada insurers typically require the following for a Dayvigo prior authorization:

1. Diagnosis code: G47.00 (insomnia, unspecified) or G47.01/G47.09 for more specific subtypes.
2. Documented failure of at least one preferred formulary sleep agent (commonly zolpidem, eszopiclone, or trazodone) with duration of trial (usually 4 to 8 weeks).
3. ISI or equivalent documentation of insomnia severity.
4. Statement that the patient does not have untreated moderate-to-severe sleep apnea.
5. Provider attestation that cognitive behavioral therapy for insomnia (CBT-I) was offered or completed [20].

The American College of Physicians 2016 guideline states: "We recommend that all adult patients receive cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder" [20]. Most insurers align their PA criteria with this guideline, so documenting a CBT-I referral or completed course is the single most effective step a provider can take to support PA approval.

Transferring an Existing Dayvigo Prescription to Nevada

Patients relocating to Nevada with an active Dayvigo prescription face a specific regulatory situation. Schedule IV prescriptions issued by an out-of-state prescriber can be filled in Nevada only if the prescriber holds a valid DEA registration (which is federally issued and valid in all states) and a current controlled-substance license in their home state [9]. Nevada pharmacies are not required to fill out-of-state Schedule IV prescriptions and may decline at their discretion.

The practical solution is to establish care with a Nevada-licensed provider before relocating or within the first 30 days of arrival. A telehealth onboarding visit of 20 to 30 minutes is usually sufficient for a provider to review prior records and issue a new Nevada prescription. Patients should bring documentation of their current dose, the duration of prior therapy, any prior authorization approvals, and a note from their previous provider.

Prescription transfers between pharmacies (e.g., from a California Walgreens to a Nevada Walgreens) are permitted for Schedule IV drugs but only one transfer is allowed per original prescription, per federal DEA rules [21]. After that single transfer, refills must be filled at the receiving pharmacy for the remainder of the prescription's life.

503A Compounding of Lemborexant in Nevada

Nevada-licensed 503A compounding pharmacies can legally compound lemborexant for an individual patient when a licensed prescriber issues a patient-specific prescription. The FDA's current policy on compounding of commercially available drugs requires that a "clinical difference" be documented, such as a need for a dose not commercially available, a required excipient change for an allergy, or a documented difficulty swallowing tablets [22].

Lemborexant is commercially available only as 5 mg and 10 mg tablets. A provider might prescribe a compounded formulation for a patient who needs a 2.5 mg dose during titration in an elderly patient with hepatic impairment, or a liquid suspension for a patient with dysphagia. Nevada's 503A pharmacies must use USP-grade active pharmaceutical ingredients and comply with Nevada State Board of Pharmacy Chapter 639 regulations [23].

The FDA has not placed lemborexant on the 503B outsourcing facility bulk drug list, which means large-scale commercial compounding of lemborexant outside a patient-specific 503A context is not currently authorized [22]. Patients should confirm their compounding pharmacy's Nevada licensure by checking the Nevada State Board of Pharmacy license lookup tool before filling.

What to Expect After Your Prescription Is Filled

Most Nevada retail pharmacies fill a new Dayvigo prescription within two to four hours if the drug is in stock. Mail-order pharmacies licensed in Nevada (including PillPack/Amazon Pharmacy and Express Scripts) typically deliver within two to four business days for standard shipping and one to two days for expedited service.

Patients should start at 5 mg and take the tablet no more than once per night, immediately before going to bed, with at least seven hours remaining before the planned wake time [2]. If 5 mg is tolerated but ineffective after seven to fourteen days, the dose may be increased to 10 mg at the provider's direction. Do not take lemborexant with or immediately after a high-fat meal; the peak concentration is delayed by approximately 2 hours in that condition, based on pharmacokinetic data in the FDA label [2].

Follow-up with the prescribing provider is recommended at four weeks to assess response, adverse effects, and any need for dose adjustment. The Nevada PMP will be queried at that visit. Most telehealth platforms that prescribe lemborexant include a 30-day follow-up message or video check-in as part of the initial care package.

For patients whose insomnia does not respond to lemborexant 10 mg after four to six weeks of consistent use, referral to a sleep specialist or a full overnight polysomnography study is the appropriate next step, per AASM guidelines [7].